Exagen Inc. Expands In-Network Access with Evolutions Healthcare Systems
SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that...
Month: March 2022
VectivBio Announces Japan License Deal and Loan Facility Agreement, Providing up to $117 Million to Fuel the Company Through Key Catalysts
Exclusive License with Asahi Kasei Pharma to develop and commercialize Apraglutide in Japan includes $30 million upfront cash payment, eligibility...
Collegium Announces Master Settlement Agreement Resolving Pending Opioid-Related Litigation
STOUGHTON, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the execution of a Master...
Universe Pharmaceuticals INC Announces Strategic Partnership with Lian-Ou Health to Develop its Digital Marketing and Sales on E-Commerce Platforms
Ji’an, Jiangxi, China, March 30, 2022 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and...
Mapi Pharma Receives U.S. Patent Covering Methods of Suppressing or Alleviating Primary or Secondary Progressive Multiple Sclerosis with a Sustained Release Glatiramer Acetate Depot
NESS ZIONA, Israel, March 30, 2022 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company...
INmune Bio, Inc. Announces Company’s CSO Dr. Mark Lowdell to Co-Host the “NK Cells in Solid Tumors” Workshop at Innate Killer Summit
The Company also Plans on Sharing INKmune™ Patient Case StudiesBoca Raton, Florida, March 30, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:...
Compass Therapeutics Announces Presentation on CTX-8371, A Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting in New Orleans
BOSTON, March 30, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biotechnology company developing proprietary antibody-based...
PepGen Continues to Build Leadership Team with Additions of Senior Vice President, Clinical Operations and Vice President, Toxicology
BOSTON, March 30, 2022 (GLOBE NEWSWIRE) -- PepGen, Inc., advancing the next generation of oligonucleotide therapies with the goal of...
Morphic to Participate in BMO Inflammation and Immunology Spotlight Series Panel
WALTHAM, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of...
Alignment Healthcare Celebrates One Year as a Public Company with Significant Revenue, Product and Membership Growth, Doubled Geographic Footprint
ORANGE, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Alignment Healthcare (NASDAQ: ALHC), a tech-enabled Medicare Advantage company, marked one year...
VYNE Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an In Vivo Model of Rheumatoid Arthritis
VYN201 demonstrated statistically significant improvement in treatment response for both endpoints at 1mg/kg and 10mg/kg dosesVYN201 also demonstrated numerically superior results...
Immutep’s Efti in Combination with MSD’s Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2nd Line Metastatic Lung Cancer Patients
All enrolled patients were 2nd line metastatic non-small cell lung carcinoma (NSCLC) patients that had confirmed progressive disease after prior...
Recce Pharmaceuticals Announces Positive Safety Data from Fourth Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
Highlights: 10 subjects in cohort four intravenously dosed; RECCE® 327 at 1,000mg, indicating to be safe and well-tolerated Independent Safety...
Aravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
HOUSTON, March 30, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to...
Prometheus Biosciences Initiates Third Phase 2 Study of PRA023 for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
- First therapeutic candidate for the treatment of SSc-ILD targeting both key fibrotic and inflammatory pathways - - ATHENA-SSc-ILD Phase...
Vyant Bio Reports Fourth Quarter and Year-End 2021 Results and Provides Strategic and Business Highlights
Highlights Focused as a pure-play drug discovery and development biotechnology companyPrimary work on the discovery of small molecule therapeutics to...
Jushi Holdings Inc. Places on The Globe and Mail’s Third-Annual Women Lead Here Benchmark of Executive Gender Diversity
BOCA RATON, Fla., March 30, 2022 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF),...
Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA
Confirmatory trial’s completion is expected in an accelerated timeline of four years with patient screening to start in MayMultiple strategies...
Alaunos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
Phase 1/2 TCR-T Library trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications; first patient consented and...
CENTOGENE Reports Fourth Quarter and Full Year 2021 Financial Results
- Full Year 2021 Total Revenue Growth of 48%, and 11% in Core Business Segments, Exceeds Guidance - Focus on...
